Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 11,401–11,500 of 15,747
SARS-CoV-2 vaccine-elicited immune responses in solid organ transplant recipients
Seo, E., Shin, E., & Jung, M. K. (2024) · Clinical Transplantation and Research · doi:10.4285/ctr.24.0062 · Cited by 2
Noda, H. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19127435 · Cited by 2
Sabadini, G., Mellado, M., Morales-Verdejo, C. A., & Mella, J. (2024) · Pharmaceuticals · doi:10.3390/ph17050606 · Cited by 3
“At the end of 2020, the first vaccine against SARS-CoV-2 was published (BNT162b2 mRNA COVID-19 Vaccine) [2,3].”
BackgroundCage, S. A., Warner, B. J., Gallegos, D. M., Cage, H., & Brown, D. (2022) · Internet Journal of Allied Health Sciences and Practice · doi:10.46743/1540-580x/2022.2180 · Cited by 2
Bouothmany, K., Bourhia, M., Chebaibi, M., Rhazzar, Z., Addoum, B., Khallouki, F., Mzibri, M. E., Elouennass, M., Ennibi, K., Almaary, K. S., et al. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202402661 · Cited by 3
“Although vaccines play crucial roles in preventing COVID-19, they can have adverse effects, such as muscle pain, chills, fever, and nausea [52], and antiviral drugs can induce common side effects [53, 54].”
Liu, X., An, R., & Wang, G. (2025) · Scientific Reports · doi:10.1038/s41598-025-26606-9 · Cited by 5
Quo Vadis, pediatrics? Upcoming challenges and opportunity in child health
Valitutti, F., & Verrotti, A. (2023) · Global Pediatrics · doi:10.1016/j.gpeds.2023.100094 · Cited by 3
A Mechanical Assay for the Quantification of Anti-RBD IgG Levels in Finger-Prick Whole Blood
Zhou, Y., Zhao, X., Jiang, Y., Lin, D. J. X., Chen, L., Wang, Y., Le, S., Li, R., & Yan, J. (2023) · ACS Sensors · doi:10.1021/acssensors.3c00393 · Cited by 2
Covid-19 Aşısının Kadın Sağlığı Üzerine Olan Etkileri
Kahyaoğlu, S., & Üstün, Y. E. (2021) · Türk Kadın Sağlığı ve Neonatoloji Dergisi · doi:10.46969/ezh.987295 · Cited by 2
Ampil, E. R., Dizon, M. D., Co, J. A. U., Ong, P. A., Annisafitrie, F. R., Saputra, L., Hsieh, S., & Yang, Y. (2022) · East Asian Archives of Psychiatry · doi:10.12809/eaap2213 · Cited by 4
Recent SARS-CoV-2 Outlook and Implications in a COVID-19 Vaccination Era
Ehianeta, T. S., Mzee, S. A. S., Kehinde, A. M., & Ehianeta, O. (2021) · Infectious Microbes & Diseases · doi:10.1097/im9.0000000000000072 · Cited by 3
“Potential concerns of ADE and VAERD following the use of SARS-CoV-2 vaccines have arisen from animal models used in assessing safety and efficacy of some SARS-CoV vaccines after enhanced diseases were observed in some animals following viral challenge, but the efficacy data of phase 3 trials of current EUA SARS-CoV-2…”
Method(2021) · doi:10.1101/2021.11.12.21266222 · Cited by 1
Müller, L., Andrée, M., Moskorz, W., Drexler, I., Hauka, S., Ptok, J., Walotka, L., Grothmann, R., Hillebrandt, J., Ritchie, A., et al. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.1027885 · Cited by 3
“This included the novel class of mRNA vaccines, Comirnaty (BioNTech/Pfizer) and Spikevax/mRNA-1273 (Moderna) (Polack et al., 2020; Baden et al., 2021).”
BackgroundHiguchi, C., Matsumoto, N., Iwasaki, Y., Yorifuji, T., Yamazaki, J., Nasu, Y., & Makino, H. (2022) · Journal of Disaster Research · doi:10.20965/jdr.2022.p0021 · Cited by 3
Chang, A., Jeng, Y., Ho, C., & Lee, P. (2024) · npj Vaccines · doi:10.1038/s41541-024-00861-9 · Cited by 2
IMMUNE THROMBOCYTOPENIA ONSET AND RELAPSE DURING THE COVID19 PANDEMIC. A MONOCENTER STUDY.
Auteri, G., Paglia, S., Mazzoni, C., et al. (2023) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2023.029 · Cited by 2
Immunogenic Comparison of Nucleic Acid-Based Vaccines Administered by Pyro-Drive Jet Injector
Tai, J. A., Nishikawa, T., Hayashi, H., Kuan, Y.-D., Yamashita, K., & Nakagami, H. (2024) · Vaccines · doi:10.3390/vaccines12070757 · Cited by 5
Soltanzadi, A., Mirmosayyeb, O., Moghaddam, A. M., Ghoshouni, H., & Ghajarzadeh, M. (2023) · Neurología (English Edition) · doi:10.1016/j.nrleng.2023.06.002 · Cited by 4
Zhang, Y., Tao, T., Li, Z., Li, H., Jiang, Q., Zhu, L., & Su, W. (2025) · Eye & ENT Research · doi:10.1002/eer3.70000 · Cited by 3
Exploring determinants of COVID-19 vaccine uptake in Tanzania: A socio-ecological perspective
Kessy, A. T., Onuekwe, C. E., Mwengee, W., Saguti, G., & Haonga, T. (2025) · Journal of Public Health in Africa · doi:10.4102/jphia.v16i3.709 · Cited by 5
“Despite the development and deployment of multiple effective vaccines, 9,10 global vaccination rates remain unequal, with particularly low uptake in many LMICs.”
Yoshida, R., Sasaki, T., & Ohsaki, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-3899998/v1 · Cited by 2
A new group at increased risk of a SARS-CoV-2 infection emerges: The recently vaccinated
Hoehl, S., Ciesek, S., Graf, J., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.012 · Cited by 2
“Between the two doses, vaccination is believed to be about 52% effective in preventing symptomatic disease [2].”
BackgroundVaccines for preventing infections in adults with solid tumours
Hirsch, C., Zorger, A.-M., Baumann, M., Park, Y. S., Bröckelmann, P. J., Mellinghoff, S. C., Monsef, I., Skoetz, N., & Kreuzberger, N. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015551.pub2 · Cited by 7
Wu, Y., Xu, S., Yau, S., & Wu, Y. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2111.01969 · Cited by 3
Kaur, A., & Krishnan, V. V. (2024) · PNAS Nexus · doi:10.1093/pnasnexus/pgae327 · Cited by 2
“For instance, the mRNA vaccines for COVID-19 are designed around the virus’s spike proteins (29, 30).”
BackgroundAcute Myopericarditis After First Dose of mRNA-1273 SARS-CoV-2 Vaccine in a Young Adult
Fadah, K., Abolbashari, M., Ojha, C. P., & Alkhateeb, H. (2022) · Cureus · doi:10.7759/cureus.22111 · Cited by 3
“The mRNA COVID-19 vaccines with two-dose regimens that are in use globally have been shown to confer 94-95% protection against severe coronavirus infection, with a promising safety profile [4].”
BackgroundSharmin, E., Majumder, K., & Ahmed, S. F. (2025) · Scientific Reports · doi:10.1038/s41598-025-12690-4 · Cited by 2
“For example, 51–59% of participants aged (18–55 years) reported fatigue after the second dose in phase III trials of certain vaccines 9 .”
InfluentialLee, J. (2020) · Osong Public Health and Research Perspectives · doi:10.24171/j.phrp.2020.11.6.01 · Cited by 2
Urology practice during the COVID-19 vaccination campaign
Ficarra, V., Novara, G., Giannarini, G., et al. (2021) · Urologia Journal · doi:10.1177/03915603211016321 · Cited by 2
SARS-CoV-2 Viroporins: A Multi-Omics Insight from Nucleotides to Amino Acids
Sarkar, M., Etheimer, P., Hannothiaux, V., & Saha, S. (2022) · Applied Microbiology · doi:10.3390/applmicrobiol2030045 · Cited by 4
Safety of mRNA-Based Vaccines for SARS CoV-2
Barda, B., & Cerny, A. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.1c00129 · Cited by 2
Latin American Scientific Production on COVID-19 Vaccines
Hernández, R. M., Esteban, R. F. C., Mamani-Benito, O. J., Chaparro, J. E. T., Saavedra-López, M. A., Calle-Ramírez, X. M., Fajardo, E. M. W., & Campos-Ugaz, O. (2022) · Ethiopian Journal of Health Sciences · doi:10.4314/ejhs.v32i2.3 · Cited by 2
Programmable nucleic acid origami nanostructures for immunotherapy
Jia, J., Liu, X., & Chen, C. (2025) · Smart Materials in Medicine · doi:10.1016/j.smaim.2025.11.004 · Cited by 3
de Lima, V. A., Nunes, J. P. S., Rosa, D. S., Ferreira, R. D. S., Oliva, M. L. V., Andreata‐Santos, R., Duarte-Barbosa, M., Janini, L. M., Maricato, J. T., Akamatsu, M. A., et al. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1353 · Cited by 1
Tani, H. (2026) · IUBMB Life · doi:10.1002/iub.70122 · Cited by 2
Watanabe, T., Hirama, T., Akiba, M., Watanabe, T., Watanabe, Y., Oishi, H., Niikawa, H., & Okada, Y. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01388-y · Cited by 3
“Vaccination has been widely demonstrated to be effective in preventing COVID-19 and reducing its severity [3, 4].”
BackgroundDiya, O., Gayed, J., Lowry, F. S., Ma, H., Bangad, V., Mensa, F., Zou, J., Xie, X., Hu, Y., Cutler, M. W., et al. (2025) · Infectious Diseases and Therapy · doi:10.1007/s40121-025-01185-4 · Cited by 4
“…favorable safety and tolerability profile that was consistent with data reported earlier from this trial for XBB.1.5-adapted and JN.1-adapted BNT162b2 [18, 20] and with phase 2/3 clinical trial data for the original and earlier bivalent versions of the vaccine in healthy adult populations [24–26].”
InfluentialSelf-citationNissilä, E., Starck, L., Aho, E., Venerandi, E., Jalkanen, P., Leskinen, K., Uvarov, P., Saavalainen, P., Julkunen, I., Kotimaa, J. P., et al. (2025) · Scandinavian Journal of Immunology · doi:10.1111/sji.70000 · Cited by 3
Impact of vaccination behavior on COVID-19 dynamics and economic outcomes
Alsammani, A., Ngonghala, C. N., & Martcheva, M. (2025) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2025084 · Cited by 7
Design of cross-reactive antigens with machine learning and high-throughput experimental evaluation
Chesterman, C. C., Desautels, T., Sierra, L. F. C., Arrildt, K. T., Zemla, A. T., Lau, E. Y., Sundaram, S., Laliberte, J. P., Chen, L., Ruby, A., et al. (2025) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2025.1580967 · Cited by 3
Wang, L., Zhou, X., Yu, W., & Lin, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1649091 · Cited by 5
The cross‐over of statistical thinking and practices: A pandemic catalyst
Garrett, A. (2022) · Pharmaceutical Statistics · doi:10.1002/pst.2221 · Cited by 2
Bloise, S., Marcellino, A., Martucci, V., Sanseviero, M., Testa, A., Giudice, E. D., Spatuzzo, M., Sermoneta, D., Ventriglia, F., & Lubrano, R. (2022) · Children · doi:10.3390/children9070993 · Cited by 2
“3%) [41], new studies on adults show high rates of hypermetabolic lymphadenopathy, identified by ultrasound results and [18F] FDG PET-CT: up to 45.”
BackgroundLee, F.-S. W., Wang, J., & Wang, C.-H. J. (2022) · Vaccines · doi:10.3390/vaccines10060902 · Cited by 2
“First, we suggest that partially vaccinated individuals should be treated as unvaccinated individuals since the BIRs for partially vaccinated individuals vary greatly in the first three weeks following the initial dose [27].”
BackgroundAn objective systematic comparison of the most common adverse events of COVID-19 vaccinesPreprint
Behrens, C., Gasperazzo, T., Samii-Moghadam, M., & Lampe, J. B. (2021) · medRxiv · doi:10.1101/2021.10.11.21264830 · Cited by 2
Ernst, C., Pires‐Afonso, Y., Bejko, D., Huberty, C., Dentzer, T. G., Wienecke-Baldacchino, A. K., Hugoson, E., Álvarez, D., Weydert, M., Vergison, A., et al. (2023) · Geriatrics · doi:10.3390/geriatrics8010019 · Cited by 2
“Studies on Comirnaty’s efficacy imply that the protection begins to take effect 12 days after the first dose, with an efficacy of around 50% between both doses [22,23].”
BackgroundSARS-CoV-2 infection despite vaccination: an under-reported COVID-19 cohort
Robbins, T., Baitule, S., Kyrou, I., Ray, P., Morgan, N., Berry, L., & Randeva, H. S. (2021) · Clinical Medicine · doi:10.7861/clinmed.let.21.2.6 · Cited by 2
Santos, C. D. J. S. E., Fonseca, R. R. D. S., Lima, S. S., Carvalho, T. M. D. S., das Mercês, L. F., Avelino, M. E. D. S., de Araújo, D. O., Freitas, F. B., Costa, I. B., Filho, A. B. D. O., et al. (2025) · Vaccines · doi:10.3390/vaccines13030283 · Cited by 3
“These data provide solid evidence that PLWH can obtain robust antibody responses after two doses of the COVID-19 vaccine and are aligned with other studies [23] and that the presence of infection alone does not interfere with the vaccine response [24].”
COVID-19 vaccination induces cross-neutralisation of sarbecoviruses related to SARS-CoV-2
West, G. E., Morse, R. B., Sievers, B. L., Abdullahi, A., Kamelian, K., Cheng, M. T. K., Bradley, J. R., Baker, S. G., Graves, B., Stark, H., et al. (2026) · npj Vaccines · doi:10.1038/s41541-026-01469-x · Cited by 3
Self-citationProfiles of US Hispanics Unvaccinated for COVID-19
(2021) · doi:10.1101/2021.09.17.21263464 · Cited by 2
Longitudinal Characterization of SARS-CoV-2 Immunity in Hemodialysis Patients Post Omicron
Karaba, A. H., Xue, J., Johnston, T. S., Traut, C. C., Dalrymple, L. S., Kossmann, R. J., Blankson, J. N., Parikh, C. R., & Ray, S. C. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.11.012 · Cited by 3
Engineering a Novel Modular Adenoviral mRNA Delivery Platform Based on Tag/Catcher Bioconjugation
Geng, K., Rice-Boucher, P. J., Kashentseva, E. A., Dmitriev, I. P., Lu, Z. H., Goedegebuure, S. P., Gillanders, W. E., & Curiel, D. T. (2023) · Viruses · doi:10.3390/v15112277 · Cited by 4
SARS-CoV-2 vaccination for immune-comprised patients: More is required
Li, H., Yu, J., & Cao, B. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100191 · Cited by 2
“1273 vaccine than after receiving the first dose [1,2].”
Decoding Undesirable Inflammatory Responses of Nucleic Acid‐Delivering Lipid Nanoparticles
Hu, R., Dou, Y., Li, C., Mu, Y., Ouyang, H., Shen, W., & Zhang, J. (2026) · Advanced Science · doi:10.1002/advs.75548 · Cited by 7
“Notably, previously developed mRNA-LNP COVID-19 vaccines achieved protective efficacy rates exceeding 90%, representing the first large-scale clinical validation of the non-viral vector technology [ 5, 6 ].”
Adverse Reactions of COVID-19 Vaccines
Jo, E. (2022) · Journal of Clinical Otolaryngology Head and Neck Surgery · doi:10.35420/jcohns.2022.33.2.92 · Cited by 2
Laurini, E., Marson, D., Aulic, S., et al. (2021) · bioRxiv · doi:10.1101/2021.05.18.444605 · Cited by 3
Mundae, R. S., Haq, Z., Adams, O. E., Parke, D. W., & Tang, P. H. (2023) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20230117-01 · Cited by 2
Arashiro, T., Solante, R., Sayo, A. R., Garcia, R. M., Kris, M., Suzuki, S., Malijan, G. M., Salazar, M. J., Salazar, M. A., Ortal-Cruz, A., et al. (2024) · Epidemiology and Infection · doi:10.1017/s0950268824001845 · Cited by 1
“Once the COVID-19 vaccines were rolled out based on trial results [2 – 7], there was a need to monitor the real-world effectiveness of the vaccines (vaccine effectiveness; VE), given concerns due to waning immunity and the emergence of variants with immune escape capacity [8 – 12].”
Tay, E., Dymock, M., López, L., Glover, C., Huang, Y. A., Bakar, K. S., Snelling, T., Marsh, J., & Wu, Y. (2024) · npj Vaccines · doi:10.1038/s41541-024-00955-4 · Cited by 3
Guan, S., Tu, M., Li, Y.-J., Wang, Y., & Yu, A. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1785592 · Cited by 2
“30–100 μg/person, intramuscular, two doses in 3–8 weeks (Polack et al., 2020; Baden et al., 2021)) as well as the LNP compositions in the present study vs . clinical research on COVID-19 vaccines differ largely, caution should be advised to directly connect those toxicities.”
de Gentile, A. S., Castellano, V. E., Weinberger, N., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3929409 · Cited by 2
Chen, M., Wang, X., Yun, Q., Lin, Y., Wu, Q., Yang, Q., Wan, D., Tian, D., & Chang, C. J. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph181910169 · Cited by 4
Zhong, G., Luo, Y., Zhao, J., Wang, M., Yang, F., Huang, J., Zou, L., Zou, X., Wang, Q., Chen, F., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.06.490932 · Cited by 3
Schaffer, A. L., Hulme, W. J., Horne, E. M. F., Parker, E. P. K., Walker, V. M., Stables, C. L., Mehrkar, A., Bacon, S., Bates, C., Goldacre, B. M., et al. (2023) · medRxiv · doi:10.1101/2023.09.07.23295194 · Cited by 2
“JCVI high risk groups prioritised for vaccination(1) Chronic respiratory disease (including poorly controlled asthma) - Chronic respiratory disease diagnosis anytime prior to index date; - Asthma admission recorded in primary care anytime prior to index date; OR - Asthma diagnosis anytime prior to index date with a pr…”
BackgroundMethodInfluentialYi, Z., Zhou, Z., Gu, Y., Xu, Y., Xiao, Z., Xiong, Z., Wang, J., Guo, H., Du, Y., Chen, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-66486-1 · Cited by 5
Assessing the benefit-risk balance of drugs. Some lessons from the COVID pandemic
Cracowski, J., Molimard, M., Richard, V. J., Roustit, M., & Khouri, C. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2368811 · Cited by 4
“Efficacy and effectiveness, as measures of vaccines benefit are given as a percentage, for example 95% protection against symptomatic Covid for the first clinical trial of tozinameran [8].”
Agent-based simulations for protecting nursing homes with prevention and vaccination strategiesPreprint
Lasser, J., Zuber, J., Sorger, J., Klager, E., Kletečka-Pulker, M., Willschke, H., Stangl, K., Stadtmann, S., Haslinger, C., Klimek, P., et al. (2020) · arXiv (Cornell University) · doi:10.17605/osf.io/hyd4r · Cited by 2
Yun, C., Lee, Y., Heo, S.-J., Kim, N., & Jung, I. (2024) · Epidemiology and Infection · doi:10.1017/s0950268824001213 · Cited by 4
“The BNT162b2 vaccine showed 95% efficacy over an average of 2-month follow-up period, leading to emergency approval by the U.S. Food and Drug Administration (FDA) [3, 4].”
Xia, Y.-L., Du, W.-W., Li, Y., Tao, Y., Zhang, Z.-B., Liu, S., Fu, Y., Zhang, K., & Liu, S.-Q. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c00334 · Cited by 2
Pirzadeh, A., Emami, S., Zuckerman, J. E., et al. (2023) · American Journal of Case Reports · doi:10.12659/ajcr.941621 · Cited by 2
Pan, M., Cao, W., Zhai, J., Zheng, C., Xu, Y., & Zhang, P. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143134 · Cited by 2
Bekbolsynov, D., Waack, A. L., Buskey, C., Bhadkamkar, S. S., Rengel, K., Petersen, W., Brown, M. L., Sparkle, T., Kaw, D., Syed, F. J., et al. (2024) · Vaccines · doi:10.3390/vaccines12010091 · Cited by 2
“A two-dose regimen of BNT162b2 demonstrated 95% effectiveness in preventing severe COVID-19 [9].”
BackgroundCOVID-19 (novel SARS-CoV-2) neurological illness
Younger, D. S. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-98818-6.00014-5 · Cited by 2
Biogenic silver nanoparticle as an adjuvant in an S1 subunit recombinant vaccine
de Freitas, S. B., Neto, A. C. P. S., Panagio, L. A., Collares, T. V., Seixas, F. K., Sousa, F. S. S., & Hartwig, D. D. (2025) · Brazilian Journal of Microbiology · doi:10.1007/s42770-025-01613-0 · Cited by 2
“S, Oxford-AstraZeneca - AZD1222/ChAdOx1, Sputnik V - GamCOVID-Vac-rAd26/rAd5) [1–3].”
Seo, M., Lee, M., Seo, Y.-J., Kim, J., Oh, J., Kim, J., Cho, Y., Chang, J., & Kim, H. (2025) · Journal of Industrial and Engineering Chemistry · doi:10.1016/j.jiec.2025.02.023 · Cited by 4
Camacho-Moll, M. E., Salinas-Martínez, A. M., Cisneros, B. T., Onofre, J. I. G., Floriano, G. N., & de León, M. B. (2023) · Vaccines · doi:10.3390/vaccines11081280 · Cited by 2
Imprinted SARS-CoV-2-Specific Memory Lymphocytes Define Hybrid ImmunityPreprint
Rodda, L. B., Morawski, P. A., Pruner, K. B., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4013029 · Cited by 2
Chen, G., Ren, Q., Zhou, J., Zhou, Y., Luo, H., Wang, Y., Li, X., Zhao, B., & Li, X. (2022) · Vaccines · doi:10.3390/vaccines10050706 · Cited by 2
Deshmukh, A. J., Ahmad, R., Cha, Y., Mulpuru, S. K., DeSimone, C. V., Killu, A. M., Mullane, S., Harrell, C., Kutyifa, V., Cheung, J. W., et al. (2024) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.16372 · Cited by 2
“11 These trials were, however, underpowered to detect rare events such as arrhythmias in the general population, more so with a lack of continuous monitoring.”
Epidemiology of COVID-19 in Jiangxi, China
Dong, Y., Ding, S. L., Zhang, J., et al. (2021) · Medicine · doi:10.1097/md.0000000000027685 · Cited by 2
Sziemel, A. M., Hwa, S.-H., Sigal, A., Tyson, G. B., Logan, N. A., Willett, B. J., & Durcan, P. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.11.439360 · Cited by 2
mRNA Vaccines to Protect Against Diseases
Thomas, S., & Abraham, A. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1884-4_5 · Cited by 2
Self-citationRecent advances in extracellular matrix-inspired nanocarriers
Rao, S., & Kiick, K. L. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2519809 · Cited by 2
“Examples include BNT162b2 and mRNA-1273, two lipid nano-particle-based COVID-19 mRNA vaccine [8,9], which were instrumental in the containment of the COVID-19 pandemic.”
Lodde, G. C., Fiedler, M., Dittmer, U., Placke, J., Jansen, P., Becker, J. C., Zimmer, L., Livingstone, E., Schadendorf, D., Sondermann, W., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.879876 · Cited by 2
Aga, A. M., Mulugeta, D., Gebreegziabxier, A., Mohammed, J., Alemu, A., Tesera, Y., Mulugeta, F., Gidisa, B., Bulti, J., Tadesse, G., et al. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-10061-4 · Cited by 3
“This trend underscores the protective effect of vaccination, consistent with numerous studies that demonstrate reduced infection rates among vaccinated individuals [6, 23].”
ResultA Sequential Predictive Power Design for a COVID Vaccine Trial
Mukherjee, R., Yajnik, P., Muehlemann, N., & Morgan-Bouniol, C. C. (2021) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2021.1979641 · Cited by 2
Evaluation of the Efficacy of COVID-19 Booster Vaccinations in Healthcare Personnel
Kim, C.-J., Bae, J. Y., Jun, K.-I., Kim, J., Son, H.-J., Chung, H., Kim, S., Kim, S., Minn, D., & Choi, H.-J. (2022) · Vaccines · doi:10.3390/vaccines10111797 · Cited by 2
Pasternak, G., Pieniawska‐Śmiech, K., Walkowiak, M., et al. (2023) · Vaccines · doi:10.3390/vaccines11050883 · Cited by 2
“in the NEJM, but there the incidence of local AE was lower after the 2nd dose and higher after the first dose [22].”
BackgroundFocal Crescentic Glomerulonephritis Following COVID-19 Viral Vector Vaccination
Wisnik-Rainville, J. M., Czyzewski, R., Demola, C., et al. (2023) · Cureus · doi:10.7759/cureus.35305 · Cited by 2
“Available data reports that the vaccines may cause: mild local side effects, some systemic events, and a very low incidence of severe adverse reactions [2,3,4].”
BackgroundLi, J., Xiao, H., Zhang, C., Liu, G., & Liu, X. (2024) · European Journal of Immunology · doi:10.1002/eji.202350916 · Cited by 2
Effect of mRNA Vaccines in Preventing COVID-19 Severe Pneumonia Among COVID-19 Patients in Japan
Matsuo, R., Matsumoto, N., Kadowaki, T., et al. (2022) · Journal of Epidemiology · doi:10.2188/jea.je20210487 · Cited by 2
Perdomo, A. D., Garrafa-Núñez, M., Meza-Caballero, M. E., Villanueva, G. P., Balbás, Y. S., & Sánchez-Paniagua-Castillo, J. (2021) · Medicina y Seguridad del Trabajo · doi:10.4321/s0465-546x2021000100002 · Cited by 7
GÜNER, N. G., Durmuş, E., Güneysu, F., Aslan, N., & Yürümez, Y. (2021) · Anaesthesia Pain & Intensive Care · doi:10.35975/apic.v25i6.1701 · Cited by 2
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.